

Synthesis of 2(1*H*)-Pyrimidinone-Containing α -Amino Acid Derivatives by Chemical Modification of L-Glutamic Acid

Akira KATOH,* Mika INOKAWA, Junko OHKANDA, and Keiryō MITSUHASHI

Department of Industrial Chemistry, Faculty of Engineering, Seikei University, Musashino-shi, Tokyo 180, Japan.

Received November 8, 1993; accepted March 4, 1994

A commercially available L-glutamic acid γ -methyl ester was converted into the corresponding urea-containing α -amino acid via the hydrazide, the azide, and then the isocyanate. The condensation of the urea-containing α -amino acid with β -diketones under acidic conditions afforded 2(1*H*)-pyrimidinone-containing α -amino acid derivatives in reasonable yields. The ¹H-NMR analysis of the dipeptide indicated that no detectable racemization had occurred during the chemical modification of L-glutamic acid.

Keywords α -amino acid derivative; 2(1*H*)-pyrimidinone; chemical modification; L-glutamic acid

Unnatural α -amino acids are important not only in designing pharmacologically active peptides but also in elucidating structure–biological activity relationships. In addition, techniques have been developed to incorporate unnatural α -amino acids into proteins.¹⁾ As a consequence, much effort has been devoted to the design and synthesis of unnatural α -amino acids,²⁾ and heterocycle-containing unnatural α -amino acids have been found to show enhanced biological activities compared with the corresponding natural α -amino acids.³⁾ There are two approaches to the synthesis of heterocycle-containing α -amino acid derivatives: (i) the synthesis of racemic amino acids and subsequent optical resolution of them,⁴⁾ and (ii) the chemical modification of the ω -functional groups in natural α -amino acids.^{3b,c)} The second approach has been little used so far. 2(1*H*)-Pyrimidinone was selected here as a heterocycle, because its synthesis and reactions have been extensively investigated in our laboratory.⁵⁾

In this paper we describe the synthesis of 2(1*H*)-pyrimidinone-containing α -amino acid derivatives by reaction of β -diketones with a urea-containing α -amino acid obtained by chemical modification of the γ -carboxyl group in L-glutamic acid.

Results and Discussion

The synthetic procedure for 2(1*H*)-pyrimidinone-containing α -amino acid derivatives is depicted in Chart 1. *tert*-Butyl and methyl groups were adopted as protecting groups for α - and γ -carboxyl, respectively. The hydrazide **2** was obtained from a commercially available L-glutamic acid γ -methyl ester (**1**) via three steps according to the literature.⁶⁾ The isocyanate **3** was prepared by the Curtius rearrangement of the corresponding azide formed by treatment of the hydrazide **2** with NaNO₂ in the presence of 1M HCl at 4°C in CHCl₃–H₂O. The conversion was followed by monitoring the absorption bands at 2150 and 2250 cm⁻¹ due to the azide and isocyanate groups, respectively.⁷⁾ The absorption band of the azide completely disappeared after the CHCl₃ solution has been kept standing overnight, followed by reflux for 10 min. The urea-containing α -amino acid **4** was obtained in 55% overall yield by passing dry NH₃ gas into a solution of the isocyanate **3** in CHCl₃. When a mixture of compound **4** and 4,4-dimethoxy-2-butanone in 2%

tert-butanolic HCl solution was heated at 70°C for 6 h, the *N*-substituted urea-containing α -amino acid **5** was isolated in a 40% yield. The ¹H-NMR spectrum shows a signal at 11.01 ppm, indicating that a strong intramolecular hydrogen bonding between NH and CO exists in CDCl₃ solution. An attempt to cyclize compound **5** was unsuccessful even under more forcing conditions. On the other hand, compound **4** was treated with 2,4-pentanedione under the same conditions to afford the desired product, *tert*-butyl 2-(benzyloxycarbonyl)amino-4-(4,6-dimethyl-2-oxo-1,2-dihydropyrimidin-1-yl)butyrate (**6a**), in 47% yield. The product showed the following data; IR: 3400 (N–H), 1712 (urethane and ester CO), 1660 (N–CO–N) cm⁻¹; ¹³C-NMR: 106.2 (d), 156.1 (s), 157.0 (s), 174.7 (s), which are very similar to the chemical shifts of the ring carbons of 1,4,6-trimethyl-2(1*H*)-pyrimidinone.⁸⁾ The reaction of the urea-containing α -amino acid **4** with other β -diketones in a similar fashion gave the corresponding α -amino acid derivatives **6b–e**. In the case of 1-phenyl-1,3-butanedione, the structural isomers **6d** and **6e**, which are separable by silica gel column chromatography, were obtained in 8 and 15% yields, respectively. The structures of **6d** and **6e** were easily assigned by means of the ¹H-NMR spectroscopy. Compound **6e** showed the benzoyl pattern at δ 7.27–7.51 and at δ 8.04–8.20.⁹⁾ Further, the signal of the olefinic proton at the 5-position of the pyrimidinone ring was shifted 0.58 ppm to lower magnetic field compared with that of compound **6a** due to the anisotropic effect of the benzene ring at the 4-position.⁹⁾

The extent of racemization during the chemical modification of L-glutamic acid was estimated by ¹H-NMR spectral examination of the dipeptides. Compound **6a** was treated with 0.03M HCl in formic acid at room temperature to give the corresponding acid **7**. Compound **7** was coupled with L-Ala-OMe and D-Ala-OMe by the *N*-ethyl-*N'*-dimethylaminopropylcarbodiimide hydrochloride (WSC·HCl)–1-hydroxybenzotriazole (HOBt) method to afford the diastereomeric dipeptides **8** and **9**, respectively (Chart 2). The chemical shifts of the methine proton of the 2(1*H*)-pyrimidinone-containing α -amino acid moiety and the two amide protons were clearly different in the two molecules, indicating that no detectable racemization had occurred during the chemical




Chart 1




Chart 2

modification.

In conclusion, synthesis of 2(1*H*)-pyrimidinone-containing α -amino acid derivatives has been accomplished by the chemical modification of the γ -carboxyl group of L-glutamic acid without detectable racemization.

Experimental

General Notes Melting points were measured on a Mel-Temp apparatus in open capillaries and are uncorrected. IR spectra were obtained with a JASCO A-100 infrared spectrophotometer. ^1H - and ^{13}C -NMR spectra were recorded on a JEOL GX-270 NMR spectrometer

using Me_4Si as an internal standard. FAB mass spectra were taken on a JEOL DX303 with a DA 5000 data system by using a Xe beam at 6 keV and a nitrobenzyl alcohol matrix. Specific rotations were recorded on a JASCO DIP-370 digital polarimeter. Thin layer chromatographic (TLC) analysis was performed on Silica gel 60F-254 with 0.2 mm layer thickness. Column chromatography was done with Merck Kieselgel 60 (230–400 mesh). Combustion analyses were performed on a Yanaco MT-3 CHN coder.

Benzoyloxycarbonyl-L-glutamic Acid α -*tert*-Butyl Ester γ -Hydrazide (2) The hydrazide **2** was prepared from a commercially available L-glutamic acid γ -methyl ester (**1**) according to the literature,⁶ mp 111 °C (lit. mp 110 °C), $[\alpha]_D^{22} -19^\circ$ ($c=0.58$, MeOH). IR (CHCl_3): 3400–3300,

1730, 1670, 740, 700 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3) δ : 1.45 (9H, s), 2.0–2.3 (4H, m), 3.4 (2H, brs), 4.0–4.3 (1H, m), 5.05 (2H, s), 7.25 (5H, s), 7.3 (1H, br s).

***N*-[3-(Benzyloxycarbonyl)amino-3-*tert*-butoxycarbonylpropyl]urea (4)** The hydrazide **2** (2.27 g, 6.5 mmol) was dissolved in 1 M HCl (19 ml) and CHCl_3 (30 ml), and cooled to 4 °C, then a solution of NaNO_2 (0.45 g, 6.5 mmol) in H_2O (7 ml) was added dropwise. After vigorous stirring for 30 min, further CHCl_3 (25 ml) was added to the mixture. The CHCl_3 layer was washed with 5% NaHCO_3 (30 ml \times 2), dried over anhydrous Na_2SO_4 , kept standing overnight and then refluxed for 10 min to give the isocyanate **3**, which was used in the next reaction without purification.

Dry NH_3 gas was introduced into a solution of isocyanate **3** in CHCl_3 on an ice bath. The solution was stirred for 3 h at room temperature, then the solvent was evaporated off under reduced pressure. The residue was chromatographed on silica gel with AcOEt as an eluant to give the urea **4** (1.25 g) in 55% overall yield as an oil, $[\alpha]_D^{25} - 32^\circ$ ($c=1.0$, MeOH). IR (CHCl_3): 3400–3200, 1700, 1670, 740, 698 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3) δ : 1.45 (9H, s), 1.8 (1H, m), 2.0 (1H, m), 3.0 (1H, m), 3.45 (1H, m), 4.3 (1H, m), 4.75 (2H, brs), 5.1 (2H, s), 5.65 (1H, brs), 5.8 (1H, brs), 7.4 (5H, s). $^{13}\text{C-NMR}$ (CDCl_3) δ : 27.9 (q), 32.0 (t), 37.3 (t), 52.7 (d), 66.9 (t), 127.3 (d), 129.1 (d), 136.3 (s), 146.3 (s), 159.4 (s), 172.8 (s). *Anal.* Calcd for $\text{C}_{17}\text{H}_{25}\text{N}_3\text{O}_5 \cdot 0.2\text{H}_2\text{O}$: C, 57.52; H, 7.16; N, 11.84. Found: C, 57.49; H, 7.16; N, 11.45.

***N*-[3-(Benzyloxycarbonyl)amino-3-*tert*-butoxycarbonylpropyl]-*N'*-(3-oxo-1-butenyl)urea (5)** A mixture of **4** (350 mg, 1 mmol) and 4,4-dimethoxy-2-butanone (120 mg, 1.2 mmol) in 2% *tert*-butanolic HCl (2.8 ml) was heated at 70 °C for 6 h. After evaporation of the solvent, the residue was dissolved in H_2O (10 ml). The aqueous solution was adjusted to pH 10 with 1 M NaOH, extracted with CH_2Cl_2 (50 ml), and dried over anhydrous MgSO_4 . The residue was chromatographed on silica gel with CHCl_3 -acetone-EtOH (100:10:2) mixture to give **5** (173 mg) in 40% yield, $[\alpha]_D^{25} - 43.1^\circ$ ($c=0.4$, MeOH). $^1\text{H-NMR}$ (CDCl_3) δ : 1.40 (9H, s), 1.80 (1H, m), 2.05 (1H, m), 2.10 (3H, s), 3.14 (1H, m), 3.53 (1H, m), 4.29 (1H, m), 5.09 (2H, s), 5.37 (1H, d, $J=6.8$ Hz), 5.70 (1H, d, $J=8.1$ Hz), 6.58 (1H, m), 7.35 (5H, s), 7.46 (1H, dd, $J=6.5$, 6.8 Hz), 11.01 (1H, d, $J=6.5$ Hz). *Anal.* Calcd for $\text{C}_{21}\text{H}_{29}\text{N}_3\text{O}_6 \cdot \text{H}_2\text{O}$: C, 57.66; H, 7.09; N, 9.61. Found: C, 57.53; H, 6.82; N, 9.37.

General Procedure for Preparation of 2(1*H*)-Pyrimidinone-Containing α -Amino Acid Derivatives. A Typical Example: *tert*-Butyl 2-(Benzyloxycarbonyl)amino-4-(4,6-dimethyl-2-oxo-1,2-dihydropyrimidin-1-yl)-butyrate (6a) A mixture of **4** (850 mg, 2.4 mmol) and 2,4-pentanedione (307 mg, 2.9 mmol) in 2% *tert*-butanolic HCl (6.6 ml) was heated at 70 °C for 12 h. After evaporation of the solvent, H_2O (50 ml) was added to the residue. The aqueous solution was neutralized with 1 M NaOH to pH 10, and extracted with CH_2Cl_2 (100 ml). The CH_2Cl_2 layer was dried over anhydrous Na_2SO_4 and then evaporated under reduced pressure. The residue was purified by column chromatography on silica gel with CHCl_3 -acetone-EtOH (100:10:5) mixture to give **6a** (472 mg) in 47% yield as an amorphous solid, $[\alpha]_D^{25} - 9.3^\circ$ ($c=1.1$, MeOH). IR (CHCl_3): 3400, 1712, 1660, 730, 670 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3) δ : 1.45 (9H, s), 2.2 (2H, m), 2.3 (6H, s), 4.0 (2H, m), 4.3 (1H, m), 5.1 (2H, s), 5.95 (1H, d, $J=8$ Hz), 6.05 (1H, s), 7.35 (5H, s). $^{13}\text{C-NMR}$ (CDCl_3) δ : 19.7 (q), 25.0 (q), 27.9 (q), 30.4 (t), 42.2 (t), 52.7 (d), 66.9 (t), 82.9 (s), 106.2 (d), 128.1 (d), 128.2 (d), 128.5 (d), 136.3 (s), 156.1 (s), 157.0 (s), 170.4 (s), 174.7 (s). *Anal.* Calcd for $\text{C}_{22}\text{H}_{29}\text{N}_3\text{O}_5 \cdot 0.8 \text{H}_2\text{O}$: C, 61.45; H, 7.0; N, 9.78. Found: C, 61.27; H, 7.07; N, 9.67.

***tert*-Butyl 2-(Benzyloxycarbonyl)amino-4-(4,5,6-trimethyl-2-oxo-1,2-dihydropyrimidin-1-yl)butyrate (6b)** Yield 37%, $[\alpha]_D^{25} - 8.89^\circ$ ($c=1.0$, MeOH). IR (CHCl_3): 3432, 1716, 1649, 737, 669 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3) δ : 1.44 (9H, s), 2.03 (3H, s), 2.16 (2H, m), 2.29 (3H, s), 2.34 (3H, s), 4.05 (2H, m), 4.28 (1H, m), 5.11 (2H, s), 6.05 (1H, d, $J=8$ Hz), 7.34 (5H, s). $^{13}\text{C-NMR}$ (CDCl_3) δ : 13.9 (q), 16.0 (q), 24.5 (q), 27.9 (q), 29.6 (t), 42.8 (t), 52.8 (d), 66.8 (t), 82.6 (s), 111.0 (s), 128.0 (d), 128.4 (d), 136.5 (s), 152.8 (s), 156.2 (s), 170.5 (s), 174.2 (s). FAB-MS m/z : 430 ($M+1$)⁺.

***tert*-Butyl 2-(Benzyloxycarbonyl)amino-4-(5-ethyl-4,6-dimethyl-2-oxo-1,2-dihydropyrimidin-1-yl)butyrate (6c)** Yield 45%, $[\alpha]_D^{25} - 8.14^\circ$ ($c=1.07$, MeOH). IR (CDCl_3): 3421, 1718, 1649, 735, 669 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3) δ : 1.07 (3H, t, $J=7.6$ Hz), 1.44 (9H, s), 2.17 (2H, m), 2.31 (3H, s), 2.37 (3H, s), 2.46 (2H, q, $J=7.6$ Hz), 4.06 (2H, m), 4.31 (1H, m), 5.11 (2H, s), 6.07 (1H, d, $J=8$ Hz), 7.34 (5H, s). $^{13}\text{C-NMR}$ (CDCl_3) δ : 13.9 (q), 15.4 (q), 21.3 (t), 23.7 (q), 27.1 (q), 30.4 (t), 42.0 (t), 52.8 (d), 66.9 (t), 82.7 (s), 117.2 (s), 128.0 (d), 128.5 (d), 136.4 (d), 152.8 (s), 156.1 (s), 156.2 (s), 170.5 (s), 174.0 (s). FAB-MS m/z : 444

($M+1$)⁺. *Anal.* Calcd for $\text{C}_{24}\text{H}_{33}\text{N}_3\text{O}_5 \cdot \text{H}_2\text{O}$: C, 62.47; H, 7.59; N, 9.11. Found: C, 62.70; H, 7.41; N, 8.97.

***tert*-Butyl 2-(Benzyloxycarbonyl)amino-4-(4-methyl-6-phenyl-2-oxo-1,2-dihydropyrimidin-1-yl)butyrate (6d) and *tert*-Butyl 2-(Benzyloxycarbonyl)amino-4-(6-methyl-4-phenyl-2-oxo-1,2-dihydropyrimidin-1-yl)-butyrate (6e)** The reaction of **4** with 1-phenyl-1,3-butanedione gave two structural isomers, which were separated by column chromatography on silica gel with CHCl_3 -acetone-EtOH (100:10:5) mixture. The first fraction afforded **6d**, yield 8%, $[\alpha]_D^{25} - 10.37^\circ$ ($c=0.75$, MeOH). IR (CHCl_3): 3425, 1716, 1653, 733, 669 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3) δ : 1.46 (9H, s), 2.0–2.21 (2H, m), 2.39 (3H, s), 3.87 (2H, m), 4.08 (1H, m), 5.03 (2H, s), 5.46 (1H, d, $J=8$ Hz), 6.10 (1H, s), 7.34–7.45 (10H, m). $^{13}\text{C-NMR}$ (CDCl_3) δ : 25.2 (q), 27.8 (q), 31.0 (t), 43.4 (t), 52.6 (d), 66.8 (t), 82.6 (s), 106.7 (d), 127.7 (d), 128.0 (d), 128.1 (d), 128.5 (d), 129.0 (d), 130.3 (s), 136.4 (s), 155.9 (s), 156.7 (s), 158.9 (s), 170.4 (s), 175.0 (s). FAB-MS m/z : 478 ($M+1$)⁺. *Anal.* Calcd for $\text{C}_{27}\text{H}_{31}\text{N}_3\text{O}_5 \cdot \text{H}_2\text{O}$: C, 65.44; H, 6.71; N, 8.48. Found: C, 65.43; H, 6.65; N, 8.52. The second fraction afforded **6e**, yield 15%, $[\alpha]_D^{25} - 3.29^\circ$ ($c=1.15$, MeOH). IR (CHCl_3): 3427, 1718, 1657, 735, 669 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3) δ : 1.46 (9H, s), 2.15–2.30 (2H, m), 2.39 (3H, s), 4.10 (2H, m), 4.32 (1H, m), 5.13 (2H, s), 5.95 (1H, d, $J=8$ Hz), 6.63 (1H, s), 7.27–7.51 (8H, m), 8.04–8.20 (2H, m). $^{13}\text{C-NMR}$ (CDCl_3) δ : 20.3 (q), 27.9 (q), 30.5 (t), 42.4 (t), 52.8 (d), 67.0 (t), 83.0 (s), 102.5 (d), 127.8 (d), 128.1 (d), 128.2 (d), 128.5 (d), 128.7 (d), 131.7 (s), 136.0 (s), 156.2 (s), 157.2 (s), 157.5 (s), 169.8 (s), 170.4 (s). FAB-MS m/z : 478 ($M+1$)⁺. *Anal.* Calcd for $\text{C}_{27}\text{H}_{31}\text{N}_3\text{O}_5 \cdot \text{H}_2\text{O}$: C, 65.44; H, 6.71; N, 8.48. Found: C, 65.53; H, 6.81; N, 8.73.

2-(Benzyloxycarbonyl)amino-4-(4,6-dimethyl-2-oxo-1,2-dihydropyrimidin-1-yl)butyric Acid (7) A solution of **6a** (500 mg, 1.2 mmol) in 0.03 M HCl in formic acid (30 ml) was stirred overnight at room temperature. After evaporation of the solvent, CHCl_3 (100 ml) was added to the residue. The CHCl_3 layer was washed with H_2O (20 ml \times 2) and dried over anhydrous MgSO_4 . Evaporation of the solvent gave the product **7** (310 mg) in 72% yield, $[\alpha]_D^{25} 5.3^\circ$ ($c=0.5$, MeOH). $^1\text{H-NMR}$ (CDCl_3) δ : 2.18 (2H, m), 2.28 (3H, s), 2.33 (3H, s), 4.06 (2H, m), 4.33 (1H, m), 5.07 (2H, s), 6.09 (1H, s), 6.41 (1H, brs), 7.31 (4H, s).

Synthesis of Diastereomeric Dipeptides 8 and 9 for Measurement of the Degree of Racemization WSC·HCl (29 mg, 0.15 mmol) in CH_2Cl_2 (0.5 ml) was added to a mixture of **7** (50 mg, 0.14 mmol), L-Ala-OMe·HCl (21.4 mg, 0.15 mmol), *N*-methylmorpholine (15 mg, 0.15 mmol), and HOBT (42.8 mg, 0.28 mmol) in dry *N,N*-dimethylformamide (DMF) (2 ml) at -10°C . The mixture was stirred for 2 h at -10°C and then for 24 h at room temperature. After evaporation of the solvent, the residue was dissolved in CHCl_3 (50 ml). The CHCl_3 layer was successively washed with 5% NaHCO_3 (20 ml \times 2), 5% citric acid (20 ml \times 2), H_2O (20 ml \times 2), and brine (20 ml \times 2), and then dried over anhydrous MgSO_4 . After evaporation of the solvent, the $^1\text{H-NMR}$ spectrum of the product (**8**) was measured. $^1\text{H-NMR}$ (CDCl_3) δ : 1.42 (3H, d, $J=7.5$ Hz), 2.12 (2H, m), 2.32 (3H, s), 2.35 (3H, s), 3.73 (3H, s), 3.91 (1H, m), 4.25 (1H, m), 4.29 (1H, m), 4.44 (1H, quintet, $J=7.5$ Hz), 5.12 (2H, s), 6.11 (1H, s), 6.51 (1H, d, $J=7.4$ Hz), 7.35 (5H, s), 7.58 (1H, d, $J=7.5$ Hz). $[\alpha]_D^{25} 3.0^\circ$ ($c=0.5$, MeOH).

The coupling of compound **7** and D-Ala-OMe·HCl was carried out in the same manner to give the dipeptide **9**. $^1\text{H-NMR}$ (CDCl_3) δ : 1.44 (3H, d, $J=7.4$ Hz), 2.11 (2H, m), 2.32 (3H, s), 2.38 (3H, s), 3.71 (3H, s), 3.86 (1H, m), 4.31 (1H, m), 4.48 (1H, quintet, $J=7.3$ Hz), 4.61 (1H, m), 5.08 (2H, s), 6.15 (1H, s), 6.37 (1H, d, $J=7.2$ Hz), 7.33 (5H, s), 8.34 (1H, d, $J=7.3$ Hz). $[\alpha]_D^{25} - 30.3^\circ$ ($c=1.0$, MeOH).

Acknowledgement The authors are grateful to Dr. T. Takahashi of Lion Corporation for measuring FAB mass spectra.

References

- 1) a) C. J. Noren, S. J. Anthony-Cahill, M. C. Griffith, P. G. Schultz, *Science*, **244**, 182 (1989); b) D. Mendel, J. Ellman, P. G. Schultz, *J. Am. Chem. Soc.*, **115**, 4359 (1993).
- 2) a) R. M. Williams, "Synthesis of Optically Active α -Amino Acids," Pergamon Press, Inc., Oxford, 1989; b) R. M. Williams, *Aldrichimica*, **25**, 11 (1992); c) R. Fitzi, D. Seebach, *Angew. Chem. Int. Ed. Engl.*, **25**, 345 (1986); d) H. Kohn, K. N. Sawhney, P. Legall, D. W. Robertson, J. D. Leander, *J. Med. Chem.*, **34**, 2444 (1991).
- 3) a) C. M. Bladon, *J. Chem. Soc., Perkin Trans. 1*, **1990**, 1151; b) N. Tamura, Y. Matsushita, T. Iwama, S. Harada, S. Kishimoto, K.

- Itoh, *Chem. Pharm. Bull.*, **39**, 1199 (1991); *c*) N. Tamura, T. Iwama, K. Itoh, *ibid.*, **40**, 381 (1992).
- 4) *a*) M. Uchida, F. Tabusa, M. Komatsu, S. Morita, T. Kanbe, K. Nakagawa, *Chem. Pharm. Bull.*, **33**, 3775 (1985); *b*) K. Yamano, K. Konno, H. Shirahama, *Chem. Lett.*, **1991**, 1541; *c*) A. El Marini, M-L. Roumestant, L. Pappalardo, P. Viallefont, *Bull. Soc. Chim. Fr.*, **1989**, 554; *d*) C. K. Acosta, M. L. Bahr, J. E. Burdett Jr, J. W. Cessac, R. A. Martinez, P. N. Rao, H. K. Kim, *J. Chem. Res., (C)*, **1991**, 110.
- 5) A. Katoh, T. Nishio, C. Kashima, *Heterocycles*, **26**, 2223 (1987).
- 6) E. Taschner, Cz Wasielewski, T. Sokolowska, J. F. Biernat, *Justus Liebigs Ann. Chem.*, **646**, 127 (1961).
- 7) K. Kawasaki, M. Maeda, J. Watanabe, H. Kaneto, *Chem. Pharm. Bull.*, **36**, 1771 (1988).
- 8) C. Kashima, A. Katoh, M. Shimizu, Y. Omote, *Heterocycles*, **22**, 2591 (1984).
- 9) C. Kashima, A. Katoh, *J. Heterocycl. Chem.*, **17**, 913 (1980).